Fundamental Data for DNDN

DENDREON C(NSDQ:DNDN)

Dendreon Corporation discovers and develops immunologically based therapeutic products for the treatment of cancer. Through the use of antigen engineering and proprietary cell separation technologies, Dendreon develops therapeutic vaccines that induce cell-mediated immunity, the body''s key defense against cancer. In addition to its products for cancer, Dendreon also intends to pursue the application of its technologies in the fields of autoimmune diseases, allergies and infectious diseases.

# Employees: 198

Address: 3005 First Avenue,Seattle,WA,USA

Phone: 206 256-4545

Fax: 206 256-0571

Website: www.dendreon.com

Email: ir@dendreon.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

Richard B. Brewer (Chrmn.)

David L. Urdal Ph.D. (Sr. V.P.; Chief Scientific Off.)

Mitchell H. Gold M.D. (Presi.; C.E.O.)

Susan B. Bayh (Dir.)

Gregory T. Schiffman (Sr. V.P.; C.F.O.; Treas.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 3/11/2010

Mean EPS (Next Qtr): ($0.29)

Mean EPS (Year): ($1.64)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 13

Shares Performance

Period	DNDN	Compare to S&P
YTD	494.76 %	392.19 %
4 Weeks	7.80 %	2.33 %
12 Weeks	14.45 %	6.58 %

Shares Information

Analyst Coverage: Y

Avg Volume: 2123964

Shares Outstanding: 115M

Market Cap: $3.15B

52 Week High: $29.91

52 Week Low: $2.61

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 1/1/1990 DNDN split by factor of 1.050

Earnings Performance

EPS Growth in Last Quarter: 66.67 %

EPS Growth in Last Year: -37.93 %

Sales Growth in Last Quarter: 0.00 %

Sales Growth in Last Quarter: -3.85 %

Financials

Qtr Book Value: $26.50

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: 29193.710